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New Era for Cardiovascular Imaging?
mplications of the Revoked National Coverage
ecision for CT Angiography on Future
maging Reimbursement
N D E C E M B E R 1 3 , 2 0 0 7 , T H E C E N T E R S F O R M E D I C A R E A N D
E D I C A I D S E R V I C E S ( C M S ) issued a proposed national coverage decision (NCD) memo-
andum for cardiac computed tomographic angiography (CTA) for thediagnosis of coronary artery disease
CAD) that would have drastically reduced coverage for Medicare beneficiaries for CTA. Under this pro-
osal, Medicare coverage for CTA would have been provided only in a small minority of patients and only
n the setting of enrollment in an approved research protocol. In its final ruling, released March 12, 2008,
MS reversed its decision and retained the existing coverage policy that gives local Medicare contractors
he discretion to reimburse according to their own policy and without a requirement for research partici-
ation. Thus CTAwill remain reimbursed byMedicare in all 50 states, with themajority of local contractorsaving similar policies.
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Che CMS has been reviewing policies re-
arding CTA coverage for several years, in-
luding a health technology assessment by the
gency for Healthcare Research and Quality
AHRQ) in 2006, a Medicare Evidence De-
elopment and Coverage Advisory Commit-
ee (MedCAC) review also in 2006, and a
ublic comment period in the summer of
006 when CMS opened a national coverage
nalysis for CTA. The proposed NCD issued
n December 2007 (1) summarized these data
nd stated that “the evidence is inadequate to
onclude that cardiac computed tomographic
ngiography (CTA) is reasonable and neces-
ary . . . for the diagnosis of coronary ar-
ery disease (CAD).” However, “the agency
elieves the evidence is promising for two cli-
ical indications and that coverage with evi-
ence development (CED) would be appro-
riate” (i.e., if a patient were enrolled in a
esearch study) but only for the following in-
ications: 1) symptomatic patients with
hronic stable angina at intermediate risk of sAD; or 2) symptomatic patients with unsta-
le angina at a low risk of short-term death
nd intermediate risk of CAD.
Further, a clinical study seeking Medicare
ayment for CTA for the diagnosis of CAD
ould have been required to address 1 or
ore of the following questions. 1) Does car-
iac CTA have the ability to diagnose or ex-
lude coronary artery disease as well as inva-
ive coronary angiography? 2) Does coronary
TA reduce the need for invasive coronary
ngiography? 3) Does coronary CTA improve
ealth outcomes for patients with acute chest
ain who present in the emergency room or
ther setting?
Finally, a study must meet a variety of spe-
ific standards, which include that the princi-
al purpose of the research study is to test
hether the intervention potentially improves
he participants’ health outcomes. All other
ses of cardiac CTA for the diagnosis of
AD would not be covered, including the
creening of asymptomatic patients for CAD.
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399ardiac CTA for uses other than the
iagnosis of CAD remains at the lo-
al contractor’s discretion.
Although this draft policy was
bandoned by CMS on March 12,
008, after consideration of public
omments including numerous re-
ponses from societies, physicians, in-
ustry, coalitions, Congress, and other
nterested parties (2), this would have
een the first time that a diagnostic
est would be required to provide evi-
ence of impact on health outcomes
ather than simply demonstrate a high
evel of test performance, such as sen-
itivity and specificity. Holding any di-
gnostic test to the high bar of posi-
ively affecting patient outcomes would
ramatically change the business and
linical landscape for imaging.
Thus, even though not imple-
ented, it is possible that the draft
olicy will have far-reaching effects.
e have invited multiple stakeholders
o present their views of the implica-
ions of CMS’s actions. Matthew Bu-
off, a cardiologist, and Pamela
oodard, a radiologist, take the view
f the physicians providing CTA ser-
ices. Sean Tunis supports evidence
evelopment, Richard Justman takes
he view of private payers, and Robert
onigberg presents a view from in-
ustry about the impact of the draft
CD.
What do they have to say? Do you
gree with them? Would you share
our opinion with us? Would you like
o start a debate? We encourage you
o visit iJACC-iNEWS in Cardio-
ource and tell us what you think. We
alue your opinion. This iNEWS col-
. .this would have been the first time t
rovide evidence of impact on health outc
evel of test performance. . .mn will be published in the May t008 issue of JACC: Cardiovascular
maging. The opinions presented here
re entirely of authors and do not re-
ect or express the position of the
merican College of Cardiology, Amer-
can College of Radiology, JACC: Car-
iovascular Imaging, or the editors.
Pamela S. Douglas, MD, MACC
Duke University Medical Center,
Durham, North Carolina
he CTA Evidence Base
s Already Robust!
atthew Budoff, MD, FACC
arbor-UCLA Medical Center,
orrance, California
A R D I A C C T A I S A N O N -
NVASIVE IMAGING TECHNOLOGY
or the diagnosis and evaluation of
AD. The amount of peer reviewed
esearch is growing at an unprecedented
ace for a new modality. Over 200
tudies were published since 2005, with
0 more coming out each month, in-
luding multicenter trials and outcome
ata. Over 2 years ago, regional Medi-
are carriers reviewed the data, pub-
ished guidelines, and appropriateness
riteria for CTA, and issued local cov-
rage determination (LCD) policies,
hich provide reimbursement in all 50
tates for CTA. In addition, United
ealth Group, Aetna, Cigna, and Hu-
ana have all decided to cover CTA
fter expert panels reviewed the avail-
ble data.
The CMS mechanism of CED is a
estricted form of a NCD reserved for
edical technologies and treatments
t a diagnostic test would be required to
es rather than simply demonstrate a highhat are promising but for which Tomparative effectiveness data do not
xist and are not likely to be available
n the near future. In contrast, the use
f CTA in a defined patient popula-
ion is supported by sufficient clinical
vidence that it should be considered
“proven” rather than a “promising”
edical technology. For instance, a
roper and beneficial use of CED is
he lung volume reduction surgery for
mphysema. A NCD with CED was
nstituted requiring enrollment of
hese patients in a trial for reimburse-
ent. The outcome of the trial
howed no benefit and a “no cover-
ge” policy was instituted. Further, as
treatment, a reimbursement stan-
ard of improvement of outcomes is
ppropriate, but CTA is a diagnostic
est and not a treatment.
For CTA, data are already available
bout improved short-term health
utcomes compared with avoiding
omplications related to invasive an-
iography (3), a reduced need for in-
asive angiography with associated
ost savings (4), and a large number
f studies have demonstrated the high
egative predictive value (99%) of
oronary CTA (5). As further evi-
ence that CTA should be reim-
ursed, consider the status of CTA of
he carotids, renal arteries, and pe-
ipheral vessels; all are covered with
ess data than exists for CTA. Simi-
arly, there are more data for cardiac
TA than for many other diagnostic
pplications of CT that are covered
y CMS.
There is no need for a CED for
TA; a robust evidence base is being
ompiled, with outcome studies and
arge diagnostic studies already under-
ay. Two multicenter trials have just
een reported and several outcome
tudies are enrolled and following pa-
ients (6,7). No other diagnostic test inha
omhere is no need for a CED for CTA. . .
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400ardiology has outcome data suggesting
mproved outcomes with testing. The
ecision that CTA be the first such
idespread imaging modality for which
emonstration of health improvement is
required condition of reimbursement
ill limit the Medicare population’s ac-
ess to a clinically established diagnostic
est that has demonstrated reduced risk
nd costs as compared with invasive
ngiography.
Policy That Promotes
vidence Development
ould Have Been
easonable!
ean Tunis, MD, MSC
enter for Medical Technology Policy
ormerly, Chief Medical Officer, CMS
OVERAGE WITH EVIDENCE DE-
ELOPMENT APPLIED BY CMS, with
ncreasing frequency over the past sev-
ral years, is intended to support the
evelopment of additional evidence
bout medical technologies when exist-
ng evidence is “promising” (8). Medi-
are applies this policy for those tech-
ologies for which there is a potential
or substantial health impact on the
edicare population and when addi-
ional studies are more likely to be con-
ucted with the benefit of reimburse-
ent. The rationale for applying CED
o CTA for symptomatic patients at in-
ermediate risk of CAD depends
eavily on whether the available evi-
ence is considered to be promising.
edicare provides unrestricted coverage
or those technologies for which the ev-
dence is determined to be “adequate”
o conclude that the item or service im-
roved health outcomes, which is the
tandard used by the agency to identify
reasonable and necessary” services.
The distinction between promising
vidence and adequate evidence is a
atter of judgment, not a matter of icience or fact (9). Experts and stake-
olders have come to different conclu-
ions regarding the quality of the exist-
ng evidence (10). Recent technology
ssessments from the Blue Cross Blue
hield Association, the Duke Evidence-
ased Practice Center, and the Califor-
ia Technology Assessment Foundation
ll concluded that the evidence for
TA does not support clinical utility.
he most recent American Heart As-
ociation statement on cardiac imag-
ng assigns a class IIa recommenda-
ion for CTA in these patients
conflicting evidence, divergence of
pinion, or both; weight of evidence/
pinion in favor) (11).
A number of multicenter trials and
egistry studies have been reported at
rofessional meetings, but have not
et been published. Virtually everyone
grees that there are no published
tudies that demonstrate improved
ealth outcomes for intermediate risk
atients who undergo CTA. Some
ote that studies showing an impact
n patient outcomes have rarely been
one for cardiac imaging and many
ther diagnostic technologies and ar-
ue that it is unreasonable to expect
uch studies as a condition of reim-
ursement. Others assert that imaging
nd diagnostic studies, as with any
ealth care intervention, must ulti-
ately be judged on whether or not
here are documented health bene-
ts—in other words, whether the ser-
ice lead to changes in care that even-
ually improve patient health.
Given this range of opinions, the
onclusion by CMS in its proposed
ecision that the evidence for CTA in
ntermediate risk patients is promising
ut not adequate was not unreason-
ble. Based on the available evidence
n CTA, it is possible to make plau-
. .the conclusion by CMS in its propoible arguments that patients obtain
et clinical benefit, and it is also pos-
ible to make plausible arguments that
he impact on patient’s health is un-
ertain and could even be harmful
e.g., from radiation exposure or addi-
ional invasive testing resulting from
alse positive tests). The best way to
istinguish between those alternatives
ould be to collect additional evi-
ence, an outcome that CED would
upport.
In the final NCD (2), the CMS
oncluded that “no adequately pow-
red study has established that im-
roved health outcomes can be caus-
lly attributed to coronary CTA for
ny well-defined clinical indication,
nd the body of evidence is of overall
imited quality and limited applicabil-
ty to Medicare patients with typical
omorbidities in community practice.”
y the agency’s usual definition of
reasonable and necessary” services,
oronary CTA did not meet the stan-
ard of being supported by evidence
f improved health outcomes. How-
ver, the agency determined that the
ack of evidence did not provide a
ufficiently strong policy basis to re-
erse the existing coverage that had
een approved by local Medicare con-
ractors. Application of CED at the
ational level would have been con-
idered a narrowing of coverage, and
his mechanism for promoting the de-
elopment of further evidence was not
etained. Conducting additional stud-
es that CMS hopes will provide evi-
ence about the impact of coronary
TA on patient outcomes will be
uch more difficult in the context of
he broad coverage now available
hrough local policies.
What is left unresolved with the fi-
al Medicare policy is the wide gap
decision that the evidence for CTA insed
ntermediate risk patients is promising but not adequate was not unreasonable. . .
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401etween what some payers consider to
e inadequate evidence of diagnostic
tility and what some clinicians and
roduct developers consider to be ad-
quate. Furthermore, no progress has
een made toward ensuring that the
reation of more reliable evidence pre-
edes, or at least accompanies, the
idespread adoption of the next gen-
ration of imaging technologies. My
ope would be that meaningful dia-
ogue continues among the stakehold-
rs about how to generate better evi-
ence on the diagnostic utility of
maging technologies more rapidly
nd efficiently and to move toward
reater consensus about the type of
vidence that is appropriate for reim-
ursement. The Center for Medical
echnology Policy was established to
upport collaborative efforts to de-
elop evidence standards and strate-
ies to efficiently develop that evi-
ence (12). Ideally, we will not
ontinually repeat the pattern of
idely adopting these technologies
ased on expert opinion and limited
vidence while hoping (too often in
ain) that someone will take responsi-
ility for conducting the studies nec-
ssary to determine with greater con-
dence whether we are actually
elping or hurting patients.
CC and ACR Should
ork Closely Together to
ssist Physicians!
amela K. Woodard, MD
ssociate Professor of Radiology,
ashington University School of
edicine
S A P H Y S I C I A N , I W A S
O N C E R N E D A B O U T A N
C D F O R C O N T R O L L E D
L I N I C A L T R I A L (CCT) reim-
ursement, especially one requiring
ED on the part of the physician in crder to get paid. Although not all
atients are optimal candidates for
CT, I feel that it is important for
hose patients who would benefit from
CT to have access to it. Moreover,
here are always exceptions to every
overage policy rule, and when excep-
ions arise, the best patient care would
llow the physician to negotiate Medi-
are or Medicaid reimbursement for
hat patient at the local level—
omething that would not be an option
f CMS instituted an NCD. Also, not
ll physicians are researchers. An NCD
uling linked to CED would have re-
uired private imaging practitioners
ith no research experience to partici-
ate in research trials in order to receive
eimbursement. Thus, 1 of 2 things
ould have occurred: Some physicians
ight have opted not to participate in
esearch trials, limiting access to CTA
o only those patients who have access
o academic institutions. Other physi-
ians might have chosen to enter pa-
ients into a clinical trial or to partici-
ate in a registry. This is acceptable if
he physician group is well-equipped
or the task, that is, the physician group
as adequate staff to prepare paperwork
or Institutional Review Board submis-
ion, capable staff for data entry, and an
nterest in research. If an imaging
roup decides to participate in a re-
earch trial or registry principally for
he purpose of reimbursement, rather
han out of academic interest, the data
ubmitted could possibly be inadequate
r inaccurate.
That being said, I am a proponent
f continuing research in cardiac
TA as we do in all fields of medi-
. .it is necessary that the major profession
uch as the American College of Radio
ardiology (ACC), continue to work togine. With the recent decision by flMS, physicians and researchers now
ave the freedom to continue to per-
orm multicenter randomized con-
rolled trials and registries based on
cientific design rather than a design
reated specifically to fill a reimburse-
ent goal.
As before the CMS determination,
t is necessary that the major profes-
ional societies with interest in cardiac
maging, such as the American Col-
ege of Radiology (ACR) and the
merican College of Cardiology
ACC), continue to work together to
romote research. Research options
nclude both hypothesis-driven, multi-
enter randomized controlled trials
nd nationwide registries. Random-
zed-controlled trials are necessary to
ursue answers to specific clinical
uestions, and registries have the po-
ential to provide long-term evidence
ased on imaging quality in the “real
orld.” Societies might have the big-
est impact on registries. Both the
CC and the ACR, through their
revious experiences with registries,
re well equipped to provide the de-
ign, infrastructure, and data analysis
o make a coronary CTA (CCTA)
egistry a success. These registries
ave the potential not only to provide
tremendous amount of data regard-
ng appropriateness and outcome, but
hey also have the potential to provide
mmediate impact on health care by
istributing quality assurance and ap-
ropriate data back to participating
enters.
I strongly believe that the CMS
ecision was the correct one. The
CTA research will continue to
societies with interest in cardiac imaging,
y (ACR) and the American College of
er to promote research. . .al
log
ethourish of its own accord, allowing
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402atients who could benefit from the
oronary CT examination to have ac-
ess to it.
e Respectfully Disagree
ith Some Conclusions
n Draft NCD!
ichard A. Justman, MD
ational Medical Director,
nited HealthCare
LTHOUGH UNITED HEALTHCARE
NDERSTANDS AND AGREES WITH
HE NEED FOR AN NCD to be based
pon published clinical evidence, and
lthough we see the potential for over-
se and inappropriate use of CTA, we
espectfully disagreed with some of the
onclusions in the proposed NCD.
The CTA is an advanced imaging
echnology intended to identify per-
ons at risk of a cardiac event. It is
ess invasive than traditional coronary
ngiography. We believe that the
ED approach should be reserved for
edical technologies and treatments
hat are promising but for which
omparative effectiveness data does
ot exist and is not likely to be avail-
ble in the near future. The use of
TA in defined patient populations is
upported by sufficient clinical evi-
ence that it should be considered a
proven” rather than a “promising”
edical technology.
Chief among these populations is the
ssessment of patients with known or
uspected CAD. United HealthCare
elieves that clinical evidence supports
he use of CCTA using 64-slice or
reater technology for patients with:
) chest pain syndrome and interme-
iate pre-angiography probability of
AD when the electrocardiogram
ECG) is uninterpretable or the pa-
ient is unable to exercise; 2) chest
ain syndrome and prior uninterpret-
ble or equivocal stress test results nexercise, profusion, or stress echo); 3)
cute chest pain and intermediate pre-
ngiography probability of CAD, no
CG changes, and negative serial en-
ymes. In addition, we also believe
hat clinical evidence supports the use
f CCTA using 64-slice or greater
echnology for the assessment of pa-
ients with known and suspected cor-
nary anomalies and morphologic as-
essment of complex congenital heart
isease including anomalies of coro-
ary circulation, great vessels, and
ardiac chambers and valves, and
orphologic evaluation of coronary
rteries in patients with new onset
eart failure to assess etiology.
We agree that CTA should not be
sed to screen persons at low risk of
AD. We agree that CTA should
ot be used in persons with high risk,
nd the candidates for coronary an-
iography and possible percutaneous
oronary interventions in any event.
e agree that the use of registries
ill be of limited value in demon-
trating the utility of CTA.
The challenging issues surrounding
he use of CTA include the potential
or overuse and inappropriate use.
here is also the potential for self-re-
erral by the worried well, use of
canners of less than 64-slice technol-
gy to perform studies, and for the
erformance of studies by inade-
uately trained physicians. Although
hese issues demand attention, we do
ot believe that the CED process is
ecessarily the best remedy. Based upon
ur evidence review, some persons for
hom CTA could potentially avoid
ore invasive procedures would be de-
he challenging issues surrounding the u
nd inappropriate use.ied coverage under this approach. 2In summary, CTA using 64-slice or
reater technology should be consid-
red reasonable and medically neces-
ary for the assessment of patients
ith known and suspected coronary
nomalies and morphologic assess-
ent of complex congenital heart dis-
ase including anomalies of coronary
irculation, great vessels, and cardiac
hambers and valves, and morphologic
valuation of coronary arteries in pa-
ients with new onset heart failure to
ssess etiology.
CD for CTA Sets a
roubling Precedent!
obert Honigberg, MD
hief Medical Officer, GE HealthCare
HE NCD FOR CORONARY CTA (1)
ROPOSED BY CMS should be a
ake-up call to the cardiology and
edical imaging community. Both
roups must be more collaborative and
roactive in generating multicenter clin-
cal data to validate the diagnostic accu-
acy of new imaging technologies for
pecifically defined patient populations.
However, CMS and other payers
eed to be part of the collaboration
ather than serving primarily as a means
or technology assessment. In the sum-
er of 2006, MedCAC convened to
ssess coronary CT and magnetic reso-
ance imaging. That report helped ac-
elerate ongoing multicenter clinical tri-
ls and registries as well as provided a
timulus for new clinical trials and
ealth economic initiatives. The cardi-
logy and imaging communities did not
xpect the next assessment for another
of CTA include the potential for overuseseyears, especially because Medicare
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403overage was in place in all 50 states
hrough local coverage decisions. In
his context, the announcement of
MS’s national coverage analysis for
TA in the summer of 2007 was
ause for much surprise and great
oncern. The key concern was that
ost of the literature for multislice
CTA was still dominated by
eaker studies on 16-slice technol-
gy and the publication lag time for
ulticenter 64-slice CTA trials
ight affect the outcome of the
nalysis by excluding key trials such
s CorE64 (Coronary Evaluation
sing Multidetector Spiral Com-
uted Tomography Angiography
sing 64 Detectors) trial, ACCU-
ACY (The Assessment by Coro-
ary Computed Tomographic An-
iography of Individuals Undergoing
oronary Angiography), SPARCSatraplatin and Prednisone Against t
print].efractory Cancer) trial, and a host
f resource use and economic stud-
es.
Although not enacted as a final
ule, the preliminary decision memo
or CTA still sets some troubling
recedents. First, the memo com-
letely negates all existing local
edicare coverage. In effect, CMS
hose the most restrictive coverage
nd most burdensome approach for
atients and providers. Coverage
ith evidence development has been
haracterized by CMS as a method
or expanding coverage, not restrict-
ng it. Second, the memo was a di-
ectional move to hold diagnostic
he final NCD for CTA will now allow
he pipeline to be published.echnologies accountable for clinical u
tector computed tomographic coronary an-
giography: appropriate for all patients with
1
1
1utcomes, which is a complex rela-
ionship dependent upon treatment
election decisions, patient compli-
nce patterns, and geographic varia-
ions in the standard of care.
The final NCD for CTA will now
llow for clinical and health economic
esearch in the pipeline to be published.
t is important that we remember the
remise of the preliminary decision
emo as a precedent to raise the bar
or outcomes data—not only for CTA
ut also for other diagnostic technolo-
ies. We need to stay ahead of the
urve to validate diagnostic accuracy in
atient populations and understand how
he technology affects the downstream
clinical and health economic research inse of health resources.E F E R E N C E S
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